Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.39 |
| ▸ | MPO | P05164 | 2/20 | 0.35 |
| ▸ | HTR1D | P28221 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31364605 | 0.90 | ALDH1A1 (0.31) | ALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL31364603 | 0.90 | ALDH1A1 (0.31) | ALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL20834976 | 0.89 | HRH4 (0.44) | HRH4HRH3MPOALDH1A1SIGMAR1 | |
| SCHEMBL20835000 | 0.88 | HRH4 (0.50) | HRH4HRH3MPODRD2ALDH1A1 | |
| SCHEMBL859796 | 0.88 | SIGMAR1 (0.45) | HRH4HRH3MPOHTR1DALDH1A1 | |
| SCHEMBL2893056 | 0.87 | HRH4 (0.38) | HRH4HRH3MPOSLC6A2HTR2A | |
| Hydrochloric Acid SCHEMBL1308667 | 0.85 | HRH4 (0.37) | HRH4HRH3MPOSLC6A2HTR2A | |
| SCHEMBL9560353 | 0.81 | MPO (0.35) | MPO | |
| SCHEMBL7333423 | 0.81 | — | — | |
| SCHEMBL7333427 | 0.81 | CA12 (0.37) | ALDH1A1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137391-A1 | Histamine H3 Agonist for use as Therapeutic Agent for a Lipid/Glucose Metabolic Disorder | MSD K.K. (JP) | 2010-06-03 | — | — | US | disclosed |
| EP-1938838-A1 | HISTAMINE H3 AGONIST FOR USE AS THERAPEUTIC AGENT FOR LIPID/GLUCOSE METABOLIC DISORDER | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137391-A1 | Histamine H3 Agonist for use as Therapeutic Agent for a Lipid/Glucose Metabolic Disorder | GPR119, HRH3, HRH4 | HRH4 3/4885HRH3 2/4885MPO 2292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.